Research programme: cardiovascular disease - ResoTher Pharma
Latest Information Update: 08 Jan 2024
At a glance
- Originator ResoTher Pharma
- Class Anti-inflammatories; Cardiovascular therapies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cardiovascular disorders
Most Recent Events
- 01 Dec 2023 RTP 200 is available for licensing as of 01 Dec 2023. https://resotherpharma.com/research/#pipeline
- 01 Dec 2023 Early research in cardiovascular disorder in Denmark (ResoTher Pharma pipeline, December 2023)